

Table of Contents

Chapter 1 Introduction

1.1 Introduction.....	1
1.2 Objectives	5
1.3 Hypothesis of Treatment	6
1.4 Plan of Work.....	6
1.5 References.....	7

Chapter 2 Literature Review

2.1 Cancer.....	10
2.2 Breast Cancer	10
2.2.1 Normal Breast	10
2.2.2 Lymphatic System of the Breast	10
2.2.3 Breast Cancer Pathophysiology.....	11
2.2.4 Breast Cancer Terminologies	12
2.2.5 Types of breast cancers.....	13
2.2.6 Breast cancer chemoprevention.....	14
2.3 Treatment for Breast Cancer.....	14
2.3.1 Surgery for breast cancer	15
2.3.2 Radiotherapy	15
2.3.3 Chemotherapy	15
2.3.4 Hormonal Therapy	16
2.3.5 Targeted and Biological Therapy.....	16
2.3.6 Other agents	16
2.4 Current Breast Cancer Research and Treatment.....	17
2.4.1 Surgery	17
2.4.2 Radiation therapy.....	17
2.4.3 Chemotherapy	17
2.4.4 Targeted and Biological therapies	17
2.5 Challenges in Development of Therapies for Cancer	18
2.6 Protein Carriers for Delivery of Cancer Therapeutics	18
2.6.1 Drug-Protein Conjugates	20
2.6.2 Protein Nanoparticles	32

2.6.3 Preparation Techniques.....	35
2.6.3.1 Desolvation (Coacervation).....	35
2.6.3.2 Nanoparticle albumin-bound technology (Nab-technology)	36
2.6.3.3 Emulsification	36
2.6.3.4 Thermal gelation.....	37
2.6.3.5 Nano spray drying.....	37
2.6.3.6 Self-assembly	38
2.6.4 Surface Modification of Protein Nanoparticles.....	38
2.6.4.1 Surfactants.....	38
2.6.4.2 PEG.....	39
2.6.4.3 Cationic polymers	39
2.6.4.4 Thermosensitive polymers	39
2.6.4.5 Folic acid.....	39
2.6.4.6 Monoclonal antibodies (mAbs).....	39
2.6.4.7 Peptides and proteins	40
2.6.5 Preclinical and Clinical Investigations of Protein Nanoparticles.....	40
2.7 Epidermal Growth Factor Receptor Targeting in Cancer.....	42
2.7.1 Biochemical and Structural Characterization of EGFR	43
2.7.2 EGFR Signaling and Trafficking	44
2.7.3 EGFR in Cancer	44
2.8 EGFR Targeting Strategies.....	45
2.8.1 Monoclonal Antibodies	46
2.8.2 TKIs.....	46
2.8.3 Antibody Based Immunoconjugates	47
2.8.4 Antisense oligodeoxynucleotides (AS ODNs).....	47
2.8.5 Other Newer Agents.....	47
2.9 Clinical Status of EGFR Inhibitors	47
2.10 Development of Resistance to EGFR Inhibitors.....	53
2.11 Potential Predictive Markers of Response to EGFR	53
2.12 Combinatorial Approaches for EGFR Targeting	56
2.13 Single chain antibodies (scFvs).....	56
2.14 Generation of scFvs.....	58
2.15 Expression of scFv	61
2.16 Purification of scFvs.....	63

2.16.1 Affinity chromatography	64
2.16.1.1 Tag ligands.....	64
2.16.1.2 Natural binding ligands	64
2.16.1.3 Biomimetic ligands	64
2.16.2 Non affinity chromatography	65
2.16.2.1 Ion exchange.....	65
2.16.2.2 Hydrophobic interaction chromatography	65
2.16.2.3 Size exclusion chromatography	65
2.16.3 Non chromatographic methodologies	65
2.16.3.1 Precipitation	66
2.16.3.2 Liquid–liquid extraction	66
2.17 Applications of ScFv antibodies	66
2.17.1 Diagnostic	66
2.17.2 Imaging	67
2.17.3 Proteomics.....	68
2.17.4 Therapeutics	69
2.18. Drug Profile	73
2.18.1 Docetaxel.....	73
2.18.2 Vinorelbine Tartrate.....	76
2.19 Excipient Profile.....	78
2.19.1 Human Serum Albumin (HSA).....	78
2.20 References:.....	81

Chapter 3 Analytical method development

3.1 Materials	102
3.2 Analytical Methods for Estimation of DTX	102
3.2.1 Estimation of DTX by UV-Visible Spectrophotometer	102
3.2.2 Estimation of DTX by Reverse Phase-HPLC (RP-HPLC) method	102
3.2.3 Analytical Method Validation	103
3.2.3.1 Linearity	103
3.2.3.2 Accuracy	103
3.2.3.3 Precision.....	104
3.2.3.4 Specificity.....	104
3.2.3.5 Detection Limit (DL) & Quantitation Limit (QL).....	104

3.3 Results and Discussion	104
3.3.1 Estimation of DTX by UV-Visible Spectrophotometer	104
3.3.2 Estimation of DTX in Formulation by RP-HPLC	107
3.3.3 Estimation of DTX in Diffusion Media by RP-HPLC	110
3.4 Analytical Methods for Estimation of VBT	112
3.4.1 Estimation of VBT by UV-Visible Spectrophotometer.....	112
3.4.2 Estimation of VBT by RP-HPLC	112
3.4.3 Analytical Method Validation	113
3.5 Results and Discussion	113
3.5.1 Estimation of VBT by UV-Visible Spectrophotometer.....	113
3.5.2 Estimation of VBT in Formulation by RP-HPLC	116
3.6 Analytical Methods for Estimation of DTX and VBT in Plasma	119
3.6.1 Estimation of DTX in plasma by RP-HPLC	119
3.6.2 Estimation of VBT in plasma by RP-HPLC method.....	120
3.6.3 Analytical Method Validation	121
3.7 Results and Discussion	121
3.7.1 Estimation of DTX in Plasma by RP-HPLC.....	121
3.7.2 Estimation of VBT in Plasma by RP-HPLC	123
3.8 Estimation of Proteins (BCA protein estimation method)	125
3.9 Results and Discussion	126
3.10 References.....	128

Chapter 4 Formulation and development: Docetaxel

4.1 Materials	129
4.2 Equipments	129
4.3 Preparation of DTX HSA Nanoparticles (DTX-HSA-NPs) by HPH	129
4.4 Preliminary Optimization of Parameters	130
4.4.1 Optimization of Formulation Parameters.....	130
4.4.1.1 DTX:HSA ratio.....	130
4.4.1.2 Concentration of DTX	130
4.4.2 Optimization of Process Parameters	130
4.4.2.1 Sonication energy	130
4.4.2.2 Pressure of HPH	130
4.4.2.3 Number of HPH cycles	131

4.5 Optimization of DTX-HSA-NPs by Box Behnken Design (BBD).....	131
4.5.1 Optimization Data Analysis.....	133
4.5.2 Response Surface Plots.....	134
4.5.3 Validation of Optimization Methodology (Check Point Analysis).....	134
4.5.4 Desirability Criteria.....	135
4.6 Lyophilization of DTX-HSA-NPs	135
4.7 Characterization of DTX-HSA-NPs.....	135
4.7.1 Particle Size	135
4.7.2 Zeta Potential	135
4.7.3 Percent Entrapment Efficiency (% EE).....	136
4.7.4 Differential Scanning Calorimetry	136
4.7.5 X-Ray Diffractometry (XRD).....	136
4.7.6 Transmission Electron Microscopy (TEM)	137
4.7.7 In-vitro drug release	137
4.7.8 Hemolysis	137
4.7.9 Stability Studies	138
4.8 Results	138
4.8.1 Preliminary Optimization	138
4.8.1.1 Optimization of Formulation Parameters:.....	138
4.8.1.2 Optimization of Process Parameters:.....	139
4.8.2 Optimization of DTX-HSA-NPs by BBD	141
4.8.2.1 Statistical Analysis of Particle Size (Response 1).....	142
4.8.2.2 Statistical Analysis of Zeta Potential (Response 2)	147
4.8.2.3 Statistical Analysis of % EE (Response 3).....	152
4.8.3 Characterization.....	159
4.8.3.1 Particle sizes, zeta potential and encapsulation efficiency.....	159
4.8.3.2 Transmission Electron Microscopy (TEM).....	161
4.8.3.3 X-ray powder diffraction results.....	161
4.8.3.4 Differential scanning calorimetry (DSC)	161
4.8.3.5 <i>In vitro</i> drug release	163
4.8.3.6 Hemolysis study.....	164
4.8.3.7 Stability of DTX-HSA-NPs.....	165
4.9 Discussion.....	166
4.10 References.....	168

Chapter 5 Formulation and development: Vinorelbine tartrate

5.1 Materials	170
5.2 Equipments	170
5.3 Preparation of VBT HSA Nanoparticles (VBT-HSA-NPs) by Desolvation.....	170
5.4 Preliminary Optimization of Parameters	171
5.4.1 Optimization of Formulation Parameters.....	171
5.4.1.1 VBT: HSA ratio	171
5.4.1.2 Concentration of VBT	171
5.4.2 Optimization of Process Parameters.....	171
5.4.2.1 Concentration and type of the desolvating agents	171
5.4.2.2 Stirring Rate.....	172
5.4.2.3 Addition system of desolvating agent	172
5.5 Optimization of VBT-HSA-NPs by Central Composite Design (CCD).....	172
5.5.1 Optimization Data Analysis.....	176
5.5.2 Response Surface Plots.....	176
5.5.3 Validation of Optimization Methodology (Check Point Analysis).....	177
5.5.4 Desirability Criteria.....	177
5.6 Lyophilization of VBT-HSA-NPs.....	177
5.7 Characterization of VBT-HSA-NPs.....	177
5.7.1 Particle Size	178
5.7.2 Zeta Potential	178
5.7.3 % Entrapment Efficiency (% EE)	178
5.7.4 Differential Scanning Calorimetry (DSC).....	179
5.7.5 Transmission Electron Microscopy (TEM)	179
5.7.6 In-vitro drug release	179
5.7.7 Stability Studies	179
5.8 Results	180
5.8.1 Preliminary Optimization	180
5.8.1.1 Optimization of Formulation Parameters.....	180
5.8.1.2 Optimization of process parameters.....	181
5.8.2 Optimization by Central Composite Design	182
5.8.2.1 Statistical Analysis of Particle Size (Response 1)	184
5.8.2.2 Statistical Analysis of % EE (Response 2)	191

5.8.3 Characterization.....	201
5.8.3.1 Particle sizes, zeta potential and encapsulation efficiency.....	201
5.8.3.2 Transmission Electron Microscopy (TEM).....	202
5.8.3.3 Differential scanning calorimetry (DSC).....	202
5.8.3.4 <i>In vitro</i> drug release	203
5.8.3.5 Stability of VBT HSA NPs	204
5.9 Discussion.....	206
5.10 References.....	208

Chapter 6 scFv expression, purification and identification

6.1 Materials	210
6.2 pDNA Transformation Method.....	210
6.3 Plasmid preparation using alkaline lysis method for isolation of pDNA.....	211
6.3.1 Preparation of reagents	211
6.3.1.1 Preparation of Luria Broth (LB) medium	213
6.3.1.2 Preparation of LB agar plates.....	213
6.3.2 Alkaline lysis method for isolation of plasmid DNA (pDNA)	213
6.4 Restriction analysis of small-scale preparations of plasmid DNA	214
6.5 Agarose Gel Electrophoresis (AGE).....	216
6.5.1 Preparation of reagents	216
6.5.2 AGE Protocol	217
6.6 Protein expression	218
6.6.1 Preparation of reagents	219
6.6.1.1 Preparation of separating (resolving) and stacking gel.....	219
6.6.1.2 Preparation of various solutions, buffers and reagents	220
6.6.2 Transformation of pCYN2 B10 scFv in E.coli BL21 (DE3).....	222
6.6.3 Protocol for Induction, Expression and Extraction of scFv protein from BL21 (DE3) E.coli	222
6.6.4 Sodium Dodecyl Sulfate Poly Acrylamide Gel Electrophoresis (SDS PAGE).....	223
6.6.4.1 Protocol for SDS-PAGE.....	225
6.6.4.2 Protocol for staining and destaining of gel.....	226
6.6.5 Protein Purification using HIS-Select™ spin column.....	227
6.6.5.1 Protocol for protein purification	227
6.7 Quantitative Protein Estimation	228

6.7.1 Preparation of BSA Standards	228
6.7.2 Preparation of BSA Working Reagent (BWR)	229
6.7.3 Assay Protocol	229
6.9 Results and Discussion	230
6.9.1 Transformation and pDNA isolation	230
6.9.2 Protein Expression and Purification	232
6.9.3 Quantification of Protein.....	233
6.9.4 Colour development during BCA protein estimation.....	233
6.10 References.....	235

Chapter 7 Targeted nanoparticles

7.1 Materials	236
7.2 Equipments	236
7.3 Preparation scFv EGFR-DTX-HSA-NPs (DTX-HSA-INPs) and scFvEGFR-VBT-HSA-NPs (VBT-HSA-INPs).....	236
7.3.1 Carbodiimide Reaction Principle	236
7.3.2 EDC Reaction Chemistry.....	237
7.4 Characterization of DTX-HSA-INPs and VBT-HSA-INPs	237
7.4.1 Particle Size	238
7.4.2 Transmission Electron Microscopy (TEM)	238
7.4.3. In-vitro drug release	238
7.4.4 Stability Studies	238
7.4.5 SDS-PAGE analysis of scFv EGFR, NPs and INPs	238
7.5 Result and Discussion	238
7.5.1 Conjugation Reaction	238
7.5.2 Particle size	239
7.5.3 Transmission Electron Microscopy (TEM)	240
7.5.4 <i>In vitro</i> drug release.....	241
7.5.4.1 DTX-HSA-INPs.....	241
7.5.4.2 <i>In vitro</i> drug release	242
7.5.5 Stability of DTX-HSA-INPs and VBT-HSA-INPs.....	244
7.5.6 SDS-PAGE analysis of scFv EGFR, NPs and INPs	246
7.6 References.....	248

Chapter 8 *In vitro* cell line studies

8.1 Introduction.....	249
8.2 Materials	249
8.2.1 Primary and Secondary Antibodies	249
8.2.2 Cell lines	249
8.2.3 Equipments.....	250
8.3 Methods	250
8.3.1 Receptor expression (EGFR) analysis by Western Blot.....	250
8.3.2 MTT assay/ Cell Cytotoxicity.....	251
8.3.3 Cellular uptake	252
8.3.3.1 Confocal microscopy	253
8.3.3.2 Fluorescence-activated cell sorting (FACS).....	254
8.3.4 Apoptosis	255
8.3.5 Cell cycle analysis	256
8.4 Results and Discussion.....	257
8.4.1 Receptor expression (EGFR) in cell lines.....	257
8.4.2 <i>In vitro</i> cytotoxicity studies (MTT assay).....	257
8.4.2 Cellular Uptake.....	266
8.4.2.1 Qualitative cellular uptake by confocal microscopy.....	266
8.4.2.2 Quantitative cellular uptake by FACS	273
8.4.4 Apoptosis studies.....	276
8.4.4.1 Docetaxel.....	276
8.4.4.2 Vinorelbine	279
8.4.5 Cell cycle analysis.....	281
8.4.5.1 Docetaxel.....	281
8.4.5.2 Vinorelbine	282
8.5 References:.....	285

Chapter 9 *In vivo* studies

9.1 Introduction.....	286
9.1.1 <i>In vivo</i> pharmacokinetic study.....	286
9.1.2 <i>In-vivo</i> acute toxicity study	287
9.1.3 Phlebitis studies.....	287
9.2 Animals.....	287

9.2.1 Pharmacokinetic study.....	287
9.2.2 Acute toxicity study.....	288
9.3 Method.....	288
9.3.1 <i>In vivo</i> pharmacokinetic studies for DTX-HSA-NPs and VBT-HSA-NPs	288
9.3.2 <i>In vivo</i> acute toxicity studies	288
9.3.3 VBT induced phlebitis studies in rats.....	289
9.4 Statistical Analysis	290
9.5 Result and Discussion	290
9.5.1 <i>In vivo</i> pharmacokinetic studies of DTX-HSA-NPs.....	290
9.5.2 <i>In vivo</i> pharmacokinetic studies for VBT-HSA-NPs	291
9.5.3 <i>In vivo</i> acute toxicity studies of DTX.....	292
9.5.4 <i>In vivo</i> acute toxicity studies of VBT	293
9.5.5 VBT induced phlebitis studies in rats.....	293
9.6 References.....	295

Chapter 10 Summary and Conclusion

10.1 Summary.....	297
10.2 Conclusion	305

List of Tables

Table 2. 1 Protein Drug Conjugates for Anticancer Therapy.....	21
Table 2. 2 Clinical Status of Antibody Drug Conjugates.....	29
Table 2. 3 List of Different Protein Carriers used for Nanoparticulate Delivery of Cancer Therapeutics	32
Table 2. 4 Observed Percentages of Tumors Overexpressing EGFR in Various Types of Cancer	45
Table 2. 5 Anti EGFR Antibodies.....	46
Table 2. 6 Clinical Status Different EGFR inhibitors.....	48
Table 2. 7 Predictive Markers of Response to EGFR.....	54
Table 2. 8 Different type of phase libraries.....	59
Table 2. 9 Preclinical and clinical status of various scFv antibodies.....	71
Table 3. 1 Calibration Data for DTX in Methanol by UV spectroscopy	105
Table 3. 2 Parameters for estimation of DTX in Methanol by UV spectroscopy	106
Table 3. 3 Calibration Data for DTX by RP-HPLC.....	108
Table 3. 4 Parameters for Estimation of DTX by RP-HPLC	109
Table 3. 5 Intraday precision and accuracy for estimation of DTX by RP-HPLC.....	110
Table 3. 6 Interday precision and accuracy for estimation of DTX by RP-HPLC.....	110
Table 3. 7 Calibration Data for DTX by RP-HPLC.....	110
Table 3. 8 Parameters for Estimation of DTX by RP-HPLC	111
Table 3. 9 Intraday precision and accuracy for estimation of DTX by RP-HPLC.....	112
Table 3. 10 Interday precision and accuracy for estimation of DTX by RP-HPLC.....	112
Table 3. 11 Calibration Data for VBT in Water by UV spectroscopy.....	114
Table 3. 12 Parameters for estimation of VBT in Water by UV spectroscopy	115
Table 3. 13 Calibration Data for VBT by RP-HPLC.....	118
Table 3. 14 Parameters for Estimation of VBT by RP-HPLC.....	118
Table 3. 15 Intraday precision and accuracy data for estimation of VBT by RP-HPLC.....	119
Table 3. 16 Interday precision and accuracy data for estimation of VBT by RP-HPLC.....	119
Table 3. 17 Calibration Data for DTX in Plasma by RP-HPLC.....	121
Table 3. 18 Parameters for Estimation of DTX in Plasma by RP-HPLC	122
Table 3. 19 Intraday precision and accuracy data for estimation of DTX in plasma by RP-HPLC	122

Table 3. 20 Interday precision and accuracy data for estimation of DTX in plasma by RP-HPLC	122
Table 3. 21 Calibration Data for VBT in Plasma by RP-HPLC	123
Table 3. 22 Parameters for Estimation of VBT in Plasma by RP-HPLC	124
Table 3. 23 Intraday precision and accuracy data for estimation of VBT in plasma by RP-HPLC	124
Table 3. 24 Interday precision and accuracy data for estimation of VBT in plasma by RP-HPLC	124
Table 3. 25 Calibration Data for BSA by UV at 562 nm.	126
Table 4. 1 Factors and levels of factors studied in a BBD	132
Table 4. 2 BBD Experimental Layout.....	133
Table 4. 3 Particle size, PDI and % EE at different DTX: HSA ratios.....	139
Table 4. 4 Particle size, PDI and stability results at different drug concentration	139
Table 4. 5 Particle size and PDI at different Homogenization pressure	140
Table 4. 6 Particle size and PDI at different no. of HPH cycle	140
Table 4. 7 Particle size, zeta potential and % EE results of DTX-HSA-NPs by BBD	141
Table 4. 8 Summary of ANOVA results (Particle Size) for Different Models	142
Table 4. 9 ANOVA for Response Surface Quadratic Model (Particle Size)	142
Table 4. 10 Summary of ANOVA results (Zeta Potential) for Different Models	147
Table 4. 11 ANOVA for Response Surface Quadratic Model (Zeta Potential)	148
Table 4. 12 Summary of ANOVA results (% EE) for Different Models.....	153
Table 4. 13 ANOVA for Response Surface Quadratic Model (% EE).....	153
Table 4. 14 ANOVA for Response Surface Quadratic Model (% EE).....	159
Table 4. 15 In-Vitro drug release data for plain DTX solution and DTX-HSA-NPs.	164
Table 4. 16 Stability data of DTX-HSA-NPs at different temperature conditions.....	165
Table 5. 1 Amount and concentration desolvating agents used for protein desolvation	172
Table 5. 2 Factors and levels of factors studied in a CCD	174
Table 5. 3 CCD Experimental Layout.....	175
Table 5. 4 Particle size, PDI and % EE at different VBT: HSA ratios	180
Table 5. 5 Particle size, PDI and stability results at different drug concentration	181
Table 5. 6 Particle size, zeta potential and % EE results of VBT-HSA-NPs by CCD	183
Table 5. 7 Summary of ANOVA results (Particle Size) for Different Models	184
Table 5. 8 ANOVA for Response Surface Quadratic Model (Particle Size)	185
Table 5. 9 Summary of ANOVA results (% EE) for Different Models.....	192

Table 5. 10 ANOVA for Response Surface Model (% EE).....	192
Table 5. 11 Comparison of observed responses of optimized formulation with predicted responses.	201
Table 5. 12 In Vitro drug release data for plain VBT and VBT-HSA-NPs	204
Table 5. 13 Stability data of VBT-HSA-NPs at different temperature conditions.....	205
Table 6. 1 Composition of different alkaline lysis solutions.....	212
Table 6. 2 Preparation of stock solutions	212
Table 6. 3 Fragment size and REs for pCYN2 B10 scFv	215
Table 6. 4 Composition for digestion studies	216
Table 6. 5 Concentration of agarose in gel for effective separation of linear pDNA	216
Table 6. 6 Reagents for AGE.....	217
Table 6. 7 Composition of separating gel and stacking gel.....	220
Table 6. 8 Compositions of buffers and reagents for protein expression & purification.....	220
Table 6. 9 Preparation of diluted BSA standards.....	229
Table 7. 1 In vitro drug release data for plain DTX solution and DTX-HSA-INPs.....	242
Table 7. 2 In vitro drug release data for plain VBT and VBT-HSA-INPs.....	243
Table 7. 3 Stability data of DTX-HSA-INPs at different temperature conditions.	244
Table 7. 4 Stability data of VBT-HSA-INPs at different temperature conditions.....	245
Table 8. 1 % Cell viability values of Taxotere, DTX-HSA-NPs and DTX-HSA-INPs in MCF-7, MDA-MB-468 and MDA-MB-231 breast cancer cell lines.	258
Table 8. 2 IC ₅₀ Value values of Taxotere, DTX-HSA-NPs and DTX-HSA-INPs in MCF-7, MDA-MB-468 and MDA-MB-231 breast cancer cell lines.	260
Table 8. 3 % Cell viability values of Navelbine, VBT-HSA-NPs and VBT-HSA-INPs in MCF-7, MDA-MB-468 and MDA-MB-231 breast cancer cell lines.	262
Table 8. 4 IC ₅₀ values of Navelbine, VBT-HSA-NPs and VBT-HSA-INPs in MCF-7, MDA-MB-468 and MDA-MB-231 breast cancer cell lines.	264
Table 8. 5 MFI of coumarin control, coumarin HSA-NPs and coumarin HSA-INPs in MDA-MB-468 cell line by FACS at different incubation time points.	274
Table 8. 6 MFI of rhodamine control, rhodamine HSA-NPs and rhodamine HSA-INPs in MDA-MB-468 cell line by FACS at different incubation time points.....	276
Table 8. 7 Apoptosis studies in MDA-MB-468 cell line after treatment of (A1/B1) Control (PBS), (A2/B2) Taxotere (A3/B3) DTX-HSA-NPs and (A4/B4) DTX-HSA-INPs by FACS.....	277

Table 8. 8 Apoptosis studies in MDA-MB-468 cell line after treatment of (A1/B1) Control (PBS), (A2/B2) Navelbine (A3/B3) VBT-HSA-NPs and (A4/B4) VBT-HSA-INPs using FACS.	280
Table 8. 9 Cell cycle analysis in MDA-MB-468 cell line after treatment of (a) Control (PBS), (b) Taxotere, (c) DTX-HSA-NPs and (d) DTX-HSA-INPs by PI staining using FACS.....	282
Table 8. 10 Cell cycle analyses in MDA-MB-468 cell line after treatment of (a) Control (PBS), (b) Navelbine, (c) VBT-HSA-NPs and (d) VBT-HSA-INPs by PI staining using FACS.....	284
Table 9. 1 <i>In vivo</i> pharmacokinetic parameters of DTX in DTX- HSA- NPs and Taxotere after i.v. injection in SD rats	290
Table 9. 2 <i>In vivo</i> pharmacokinetic parameters of VBT in VBT-HSA-NPs and Navelbine after i.v. injection in SD rats	292

List of Figures

Figure 1. 1 Mechanism of passive and active targeting	3
Figure 2. 1 Normal Structure of the Breast	11
Figure 2. 2 Lymphatic System of the Breast	11
Figure 2. 3 Overview of signal transduction pathways involved in apoptosis	12
Figure 2. 4 Types of Breast Cancer.....	13
Figure 2. 5 Types of monoclonal antibodies and their fragments.	57
Figure 2. 6 Generation and selection of scFv by hybridoma, phage display and ribosomal display technologies.....	59
Figure 2. 7 Expression of scFv in bacterial and mammalian cells.	62
Figure 2. 8 General steps involved in production and purification of scFv.	63
Figure 2. 9 Applications of scFv in different areas as diagnostic, research and therapeutic tool.	71
Figure 3. 1 UV Spectrum of DTX in Methanol.....	105
Figure 3. 2 Standard Plot of DTX in Methanol by UV spectroscopy	106
Figure 3. 3 UV spectrum of DTX, HSA and mixture of DTX and HSA.....	107
Figure 3. 4 First derivative spectrum of DTX, HSA and mixture of DTX and HSA	107
Figure 3. 5 Chromatogram of DTX at λ_{max} of 229 nm.....	108
Figure 3. 6 Standard Plot of DTX by RP-HPLC	109
Figure 3. 7 Standard Plot of DTX by RP-HPLC	111
Figure 3. 8 UV Spectrum of VBT in Water	114
Figure 3. 9 Standard Plot of VBT in Water by UV spectroscopy	115
Figure 3. 10 UV spectrum of VBT, HSA and mixture of VBT and HSA	116
Figure 3. 11 First derivative spectrum of VBT, HSA and mixture of VBT and HSA	116
Figure 3. 12 Chromatogram of VBT at λ_{max} of 271.2 nm	117
Figure 3. 13 Standard Plot of VBT by RP-HPLC.....	117
Figure 3. 14 Standard Plot of DTX in Plasma by RP-HPLC	121
Figure 3. 15 Standard Plot of VBT in Plasma by RP-HPLC.....	123
Figure 3. 16 Standard Plot of BSA by UV	127
Figure 4. 1 Diagrammatic representation of a BBD for three factors.....	131
Figure 4. 2 Effect of Drug on Particle Size	144
Figure 4. 3 Effect of Albumin on Particle Size	144
Figure 4. 4 Effect of HP on Particle Size	145

Figure 4. 5 Response surface showing combined effect of drug and albumin on particle size.	145
Figure 4. 6 Response Surface Showing Combined Effect of Drug and HP on Particle Size.	146
Figure 4. 7 Response Surface Showing Combined Effect of Albumin and HP on Particle Size.	146
Figure 4. 8 Effect of Drug on Zeta Potential	149
Figure 4. 9 Effect of Albumin on Zeta Potential	150
Figure 4. 10 Effect of HP on Zeta Potential	150
Figure 4. 11 Response Surface Showing Combined Effect of Drug and Albumin on Zeta Potential.	151
Figure 4. 12 Response Surface Showing Combined Effect of Drug and HP on Zeta Potential.	151
Figure 4. 13 Response Surface Showing Combined Effect of Albumin and HP on Zeta Potential.	152
Figure 4. 14 Effect of Drug on % EE.....	154
Figure 4. 15 Effect of Albumin on % EE.....	155
Figure 4. 16 Effect of HP on % EE.....	155
Figure 4. 17 Response Surface Showing Combined Effect of Drug and Albumin on % EE.	156
Figure 4. 18 Response Surface Showing Combined Effect of Drug and HP on % EE.	156
Figure 4. 19 Response Surface Showing Combined Effect of Albumin and HP on % EE...	157
Figure 4. 20 Desirability plot for optimized formulations	158
Figure 4. 21 Particle size distributions of optimized DTX-HSA-NPs	160
Figure 4. 22 Zeta potential of optimized DTX-HSA-NPs	160
Figure 4. 23 TEM images of DTX-HSA-NPs	161
Figure 4. 24 XRD spectra of pure DTX (A), Lyophilized blank NPs (B), Physical mixture of DTX and blank NPs (C) and DTX-HSA-NPs (D)	162
Figure 4. 25 DSC thermogram of DTX (A), Human serum albumin, (B) Physical mixture of DTX and human serum albumin (C) and DTX-HSA-NPs (D).....	163
Figure 4. 26 <i>In Vitro</i> drug release pattern	164
Figure 4. 27 Comparative changes in particle size with temperature during stability.....	166
Figure 5. 1 Diagrammatic representation of a CCD	173
Figure 5. 2 Effect of Albumin Concentration on Particle Size.....	186

Figure 5. 3 Effect of Vinorelbine Amount on Particle Size	187
Figure 5. 4 Effect of pH on Particle Size	187
Figure 5. 5 Effect of Glutardaldyde Concentration on Particle Size	188
Figure 5. 6 Response Surface Showing Combined Effect of Vinorelbine Amount and Albumin Concentration on Particle Size	188
Figure 5. 7 Response Surface Showing Combined Effect of pH and Albumin Concentration on Particle Size.....	189
Figure 5. 8 Response Surface Showing Combined Effect of Glutardaldyde Concentration and Albumin Concentration on Particle Size.....	189
Figure 5. 9 Response Surface Showing Combined Effect of Vinorelbine Amount and pH on Particle Size.....	190
Figure 5. 10 Response Surface Showing Combined Effect of Vinorelbine Amount and Glutardaldyde Concentration on Particle Size	190
Figure 5. 11 Response Surface Showing Combined Effect of pH and Glutardaldyde Concentration on Particle Size	191
Figure 5. 12 Effect of Albumin Concentration on Encapsulation Efficiency	194
Figure 5. 13 Effect of Vinorelbine Amount on Encapsulation Efficiency	194
Figure 5. 14 Effect of pH on Encapsulation Efficiency	195
Figure 5. 15 Effect of Glutaraldehyde Concentration on Encapsulation Efficiency	195
Figure 5. 16 Response Surface Showing Combined Effect of Vinorelbine Amount and Albumin Concentration on Encapsulation Efficiency	196
Figure 5. 17 Response Surface Showing Combined Effect of pH and Albumin Concentration on Encapsulation Efficiency.....	196
Figure 5. 18 Response Surface Showing Combined Effect of Albumin Concentration and Glutardaldyde Concentration on Encapsulation Efficiency	197
Figure 5. 19 Response Surface Showing Combined Effect of pH and Vinorelbine Amount on Encapsulation Efficiency	197
Figure 5. 20 Response Surface Showing Combined Effect of pH and Glutardaldyde Concentration on Encapsulation Efficiency	198
Figure 5. 21 Response Surface Showing Combined Effect of pH and Glutardaldyde Concentration on Encapsulation Efficiency	198
Figure 5. 22 Desirability Plot for Optimized Formulations	200
Figure 5. 23 Particle size distributions of optimized VBT HAS NPs by Malvern Zetasizer	201
Figure 5. 24 Zeta Potential of optimized VBT HSA NPs by Malvern Zetasizer	202

Figure 5. 25 TEM images of VBT-HSA-NPs	202
Figure 5. 26 DSC thermogram of vinorelbine (A), Human serum albumin, (B) Physical mixture of vinorelbine and human serum albumin (C) and VBT HSA NPs (D).	203
Figure 5. 27 <i>In Vitro</i> drug release pattern	204
Figure 5. 28 Comparative changes in particle size with temperature during stability.....	205
Figure 6. 1 pCYN2 B10 scFv	215
Figure 6. 2 Schematic representation of protein synthesis.....	218
Figure 6. 3 SDS PAGE Flowchart.	224
Figure 6. 4 Transformed cells in E.coli DH5	230
Figure 6. 5 Transformed cells in E.coli BL21 (DE3).....	231
Figure 6. 6 pDNA (pCYN2 B10 scFv) by Xho I digestion.....	232
Figure 6. 7 Protein expression in cell lysate and purified scFv band on SDS PAGE.....	233
Figure 6. 8 Color of protein samples before incubation during BCA protein estimation test	234
Figure 6. 9 Color of protein samples after incubation during BCA protein estimation test .	234
Figure 7. 1 Particle size distributions of optimized DTX-HSA-INPs.....	239
Figure 7. 2 Particle size distributions of optimized VBT-HSA-INPs.....	240
Figure 7. 3 TEM images of DTX-HSA-INPs.....	240
Figure 7. 4 TEM images of VBT-HSA-INPs	241
Figure 7. 5 <i>In vitro</i> drug release pattern of DTX-HSA-INPs	242
Figure 7. 6 <i>In vitro</i> drug release pattern of DTX-HSA-INPs	244
Figure 7. 7 Comparative changes in particle size of DTX-HSA-INPs with different temperature conditions during stability	245
Figure 7. 8 Comparative changes in particle size of VBT-HSA-INPs with different temperature conditions during stability.....	246
Figure 7. 9 SDS Page Analysis for confirmation of conjugation reaction forming INPs	247
Figure 8. 1 Receptor expression analysis in cell lines.	257
Figure 8. 2 Cytotoxicity of Different Formulations of DTX in MCF-7 Cell-line.	258
Figure 8. 3 Cytotoxicity of Different Formulations of DTX in MDA-MB-468 Cell-line. ...	259
Figure 8. 4 Cytotoxicity of Different Formulations of DTX in MDA-MB-231 Cell-line. ...	259
Figure 8. 5 Cytotoxicity of Different Formulations of DTX in MCF-7 Cell-line.	259
Figure 8. 6 Cytotoxicity of Different Formulations of DTX in MDA-MB-468 Cell-line. ...	260
Figure 8. 7 Cytotoxicity of Different Formulations of DTX in MDA-MB-231 Cell-line. ...	260

Figure 8. 8 Comparative IC ₅₀ Values of DTX formulations in MCF-7, MDA-MB-468 and MDA-MB-231 breast cancer cell lines (6 h).....	261
Figure 8. 9 Comparative IC ₅₀ Values of DTX formulations in MCF-7, MDA-MB-468 and MDA-MB-231 breast cancer cell lines (24 h).....	261
Figure 8. 10 Cytotoxicity of Different Formulations of VBT in MCF-7 Cell-line.	262
Figure 8. 11 Cytotoxicity of Different Formulations of VBT in MDA-MB-468 Cell-line. .	263
Figure 8. 12 Cytotoxicity of Different Formulations of VBT in MDA-MB-231 Cell-line. .	263
Figure 8. 13 Cytotoxicity of Different Formulations of VBT in MCF-7 Cell-line.	263
Figure 8. 14 Cytotoxicity of Different Formulations of VBT in MDA-MB-468 Cell-line. .	264
Figure 8. 15 Cytotoxicity of Different Formulations of VBT in MDA-MB-231 Cell-line. .	264
Figure 8. 16 Comparative IC ₅₀ Values of VBT formulations in MCF-7, MDA-MB-468 and MDA-MB-231 breast cancer cell lines (24 h).....	265
Figure 8. 17 Comparative IC ₅₀ Values of VBT formulations in MCF-7, MDA-MB-468 and MDA-MB-231 breast cancer cell lines (60 h).....	265
Figure 8. 18 Qualitative uptake of coumarin loaded formulations by confocal microscopy in MDA-MB-468 cell lines	267
Figure 8. 19 Qualitative uptake of coumarin loaded formulations by confocal microscopy in MDA-MB-231 cell lines.	268
Figure 8. 20 Qualitative uptake of rhodamine loaded formulations by confocal microscopy in MDA-MB-468 cell lines.	269
Figure 8. 21 Qualitative uptake of rhodamine loaded formulations by confocal microscopy in MDA-MB-231 cell lines.	270
Figure 8. 22 Qualitative uptake of coumarin- HSA-INPs by confocal microscopy in MCF-7, MDA-MB-231 and MDA-MB-468 cell lines	271
Figure 8. 23 Qualitative uptake of rhodamine- HSA-INPs by confocal microscopy in MCF-7, MDA-MB-231 and MDA-MB-468 cell lines	272
Figure 8. 24 Quantitative intracellular uptake of coumarin control, coumarin HSA-NPs and coumarin HSA-INPs in MDA-MB-468 cell line by FACS	273
Figure 8. 25 Quantitative intracellular uptake (MFI) comparison of coumarin control, coumarin HSA-NPs and coumarin HSA-INPs in MDA-MB-468 cell line by FACS at different incubation time points.....	274
Figure 8. 26 Quantitative intracellular uptake of rhodamine control, rhodamine HSA-NPs and rhodamine HSA-INPs in MDA-MB-468 cell line by FACS	275

Figure 8. 27 Quantitative intracellular uptake (MFI) comparison of rhodamine control, rhodamine HSA-NPs and rhodamine HSA-INPs in MDA-MB-468 cell line by FACS at different incubation time points	275
Figure 8. 28 Apoptosis estimation in MDA-MB-468 cell line.....	277
Figure 8. 29 Apoptosis estimation in MDA-MB-468 cell line.....	278
Figure 8. 30 Apoptosis estimation in MDA-MB-468 cell line.....	279
Figure 8. 31 Apoptosis estimation in MDA-MB-468 cell line.....	280
Figure 8. 32 Cell cycle analysis in MDA-MB-468 cell line after treatment of (a) Control (PBS), (b) Taxotere, (c) DTX-HSA-NPs and (d) DTX-HSA-INPs by PI staining using FACS.....	282
Figure 8. 33 Cell cycle analyses in MDA-MB-468 cell line after treatment of (a) Control (PBS), (b) Navelbine, (c) VBT-HSA-NPs and (d) VBT-HSA-INPs by PI staining using FACS.....	283
Figure 9. 1 Mean plasma concentration–time profiles of DTX following IV injection of two different formulations of DTX at a dose of 10 mg/kg in rats.....	291
Figure 9. 2 Mean plasma concentration time profiles of VBT following IV injection of two different formulations of VBT at a dose of 5 mg/kg in rats.....	292
Figure 9. 3 Plain VBT Solution	293
Figure 9. 4 Albumin+ VBT Physical mixtures.....	294
Figure 9. 5 VBT-HSA-NPs	294
Figure 9. 6 VBT-HSA-INPs	294

LIST OF ABBREVIATIONS

- AGE : Agarose Gel Electrophoresis
- APS : Ammonium persulfate
- BBD : Box Behnken Design
- BCA : Bicinchoninic acid
- CCD : Central Composite Design
- DAPI : 4,6-diamidino-2-phenylindole
- DCIS : Ductal carcinoma in situ
- DL : Detection Limit
- DSC : Differential Scanning Calorimetry
- DTT : Dithiothreitol
- DTX : Docetaxel trihydrate
- EDC : Ethyl-3-dimethyl amino propyl carbodiimide
- EGFR : Epidermal growth factor receptor
- FBS : Fetal bovine serum
- FITC : Fluorescein isothiocyanate
- HPH : High Pressure Homogenizer
- HSA : Human serum albumin
- IDC : Invasive (or infiltrating) ductal carcinoma
- ILC : Invasive lobular carcinoma
- INPs : Immunonanoparticles
- IPTG : Isopropyl -D-1-thiogalactopyranoside
- LB : Luria Broth
- LICS : Lobular carcinoma in situ
- MEM : Medium essential medium
- MTT : 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
- MWCO : Molecular Weight Cutoff
- NPs : Nanoparticles
- PDI : Polydispersity index
- QL : Quantitation Limit
- RMFI : Relative mean fluorescence intensity

- RSD : Relative standard deviation
- RSM : Response surface methodology
- scFv : Single chain fragment variable
- SDS-PAGE : Sodium Dodecyl Sulfate Poly Acrylamide Gel Electrophoresis
- TAE : Tris-Acetate-EDTA
- TCEP : Tris(2-carboxyethyl) phosphine
- TEM : Transmission Electron Microscopy
- TEMED : Tetramethylethylenediamine
- VBT : Vinorelbine tartrate
- XRD : X-ray diffraction